[go: up one dir, main page]

PE20190209A1 - Anticuerpos anti-factor bb del complemento y uso de estos - Google Patents

Anticuerpos anti-factor bb del complemento y uso de estos

Info

Publication number
PE20190209A1
PE20190209A1 PE2018001946A PE2018001946A PE20190209A1 PE 20190209 A1 PE20190209 A1 PE 20190209A1 PE 2018001946 A PE2018001946 A PE 2018001946A PE 2018001946 A PE2018001946 A PE 2018001946A PE 20190209 A1 PE20190209 A1 PE 20190209A1
Authority
PE
Peru
Prior art keywords
antibodies
factor
complement
seq
complement anti
Prior art date
Application number
PE2018001946A
Other languages
English (en)
Inventor
Sandip Panicker
Graham Parry
Karen Christopherson
Tony Sang Young Byun
Original Assignee
Bioverativ Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa Inc filed Critical Bioverativ Usa Inc
Publication of PE20190209A1 publication Critical patent/PE20190209A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LSe refiere a un anticuerpo especifico para el factor Bb del complemento, comprende CDRs de cadena ligera como SEQ ID NO: 7,15, 23, 31, 39, 47 y CDRs de cadena pesada como SEQ ID NO: 8, 16, 24, 32, 40 y 48. Los anticuerpos anti-Bb son utiles para el tratamiento de trastornos mediados por el complemento.
PE2018001946A 2016-04-04 2017-04-03 Anticuerpos anti-factor bb del complemento y uso de estos PE20190209A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662317897P 2016-04-04 2016-04-04
PCT/US2017/025784 WO2017176651A1 (en) 2016-04-04 2017-04-03 Anti-complement factor bb antibodies and uses thereof

Publications (1)

Publication Number Publication Date
PE20190209A1 true PE20190209A1 (es) 2019-02-07

Family

ID=60000646

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001946A PE20190209A1 (es) 2016-04-04 2017-04-03 Anticuerpos anti-factor bb del complemento y uso de estos

Country Status (23)

Country Link
US (3) US10934347B2 (es)
EP (1) EP3452510A4 (es)
JP (3) JP6967528B2 (es)
KR (2) KR20240096672A (es)
CN (2) CN116790614A (es)
AU (2) AU2017246794B2 (es)
BR (1) BR112018070357A2 (es)
CA (1) CA3019332A1 (es)
CL (1) CL2018002810A1 (es)
CO (1) CO2018010827A2 (es)
CR (1) CR20180529A (es)
DO (1) DOP2018000219A (es)
EA (1) EA201892225A1 (es)
EC (1) ECSP18082302A (es)
IL (3) IL295288B2 (es)
MA (1) MA44878A (es)
MX (2) MX2018012176A (es)
MY (1) MY194603A (es)
PE (1) PE20190209A1 (es)
PH (1) PH12018502137A1 (es)
SG (1) SG11201808525UA (es)
TN (1) TN2018000341A1 (es)
WO (1) WO2017176651A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201906652T4 (tr) 2010-07-28 2019-05-21 Gliknik Inc Kademeli multimerize immünoglobülin fc bileşimleri oluşturmak için doğal insan protein fragmanları içeren füzyon proteinleri.
SI3325011T1 (sl) 2015-07-24 2021-02-26 Gliknik Inc. Fuzijski proteini humanih proteinskih fragmentov za tvorbo pravilnih multimeriziranih imunoglobulin FC sestavkov s povečanim vezanjem komplementa
IL295288B2 (en) 2016-04-04 2024-08-01 Bioverativ Usa Inc Anti-complement factor BB antibodies and their uses
BR112019009495A2 (pt) 2016-12-09 2019-08-06 Gliknik Inc métodos de tratamento de distúrbios inflamatórios com compostos de fc multivalentes
AU2017371179B2 (en) 2016-12-09 2022-07-14 Gliknik Inc. Manufacturing optimization of GL-2045, a multimerizing stradomer
CN110944672A (zh) * 2017-01-17 2020-03-31 得克萨斯A&M大学系统 用于改善载物分子向靶细胞的内溶酶体区室递送的内溶酶体靶向偶联物
TWI823868B (zh) * 2017-10-11 2023-12-01 美商生物維瑞提夫美國公司 誘導補體活性之方法
CA3085945A1 (en) * 2017-12-19 2019-06-27 The University Of North Carolina At Chapel Hill Methods and compositions for delivery of viral vectors across the blood-brain barrier
AU2020304415A1 (en) * 2019-06-27 2022-02-17 Verseau Therapeutics, Inc. Anti-CD53 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
JP7631296B2 (ja) * 2019-07-17 2025-02-18 ジェミニ・セラピューティクス・サブ・インコーポレイテッド Ｈ因子増強性抗体及びその使用
WO2021167949A1 (en) * 2020-02-18 2021-08-26 Children's Hospital Medical Center Compositions and methods for treating liver disease
CN115702165A (zh) 2020-04-20 2023-02-14 建新公司 人源化抗补体因子Bb抗体及其用途
EP4216946A4 (en) 2020-09-23 2024-11-13 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4866132A (en) 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5256334A (en) 1988-09-08 1993-10-26 The Research Foundation Of The State University Of New York Homogeneous radiopaque polymer-organobismuth composites
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
CA2115742A1 (en) 1991-08-20 1993-03-04 Ronald G. Crystal Adenovirus mediated transfer of genes to the gastrointestinal tract
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
US5346981A (en) 1993-01-13 1994-09-13 Miles Inc. Radiopaque polyurethanes
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
PL186073B1 (pl) 1993-10-25 2003-10-31 Canji Preparat farmaceutyczny, zwłaszcza do terapii genowej
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
CN1160469C (zh) 1994-12-09 2004-08-04 帝国大学改革有限公司 基因的鉴定
WO1996019487A1 (en) 1994-12-22 1996-06-27 Nissan Chemical Industries, Ltd. Organobismuth derivatives and process for producing the same
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
DK0939647T4 (da) 1996-08-27 2006-10-23 Novartis Vaccines & Diagnostic Neisseria Meningitidis-serogruppe B-glycokonjugat og fremgangsmåde til anvendelse deraf
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
JP2001525470A (ja) 1997-12-12 2001-12-11 マクロメド・インコーポレーテッド タンパク修飾のためのヘテロ官能化星形ポリ（エチレングリコール）
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2727425T3 (es) 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
EP1713503B1 (en) 2004-02-10 2013-07-31 The Regents of the University of Colorado, a Body Corporate Inhibition of factor b, the alternative complement pathway and methods related thereto
CN102603895B (zh) 2004-06-18 2016-09-28 Ambrx公司 新颖抗原结合多肽和其用途
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
EP2500030B2 (en) 2005-11-04 2018-08-08 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
RU2456298C2 (ru) * 2005-12-20 2012-07-20 ЭсБиАй БАЙОТЕК КО., ЛТД. Антитело против ilt17
CN101970002B (zh) * 2007-08-27 2016-05-18 诺福麦德治疗学股份有限公司 用因子Bb特异性抗体抑制补体活化的方法
JP2011503094A (ja) * 2007-11-08 2011-01-27 ジェネンテック， インコーポレイテッド 抗ｂ因子抗体およびそれらの使用
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
RU2011125366A (ru) 2008-12-05 2013-01-10 Ангиочем Инк. Конъюгаты терапевтических пептидов и их применение
EP2483307A1 (en) 2009-09-29 2012-08-08 Fraunhofer USA, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
HK1199837A1 (en) 2011-10-27 2015-07-24 Nkt Therapeutics Inc. Humanized antibodies to inkt
PE20190658A1 (es) 2012-02-24 2019-05-08 Abbvie Stemcentrx Llc Moduladores y metodos de empleo novedosos
US9243070B2 (en) * 2012-04-03 2016-01-26 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor Bb antibodies and uses thereof
WO2014044793A2 (en) 2012-09-20 2014-03-27 Max-Delbrück-Centrum für Molekulare Medizin Cd22-binding peptides
PT2914291T (pt) * 2012-11-02 2022-05-05 Bioverativ Usa Inc Anticorpos anti-complemento c1s e suas utilizações
RU2019109456A (ru) 2013-02-22 2019-04-10 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые конъюгаты антител и их применения
US9260527B2 (en) * 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
JP6643244B2 (ja) 2014-02-27 2020-02-12 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 補体因子Ｂｂ抗体
HK1250033A1 (zh) 2015-07-13 2018-11-23 Cytomx Therapeutics Inc. 抗-pd-1抗体、可活化的抗-pd-1抗体、及其使用方法
IL295288B2 (en) 2016-04-04 2024-08-01 Bioverativ Usa Inc Anti-complement factor BB antibodies and their uses
TWI823868B (zh) 2017-10-11 2023-12-01 美商生物維瑞提夫美國公司 誘導補體活性之方法
CN115702165A (zh) 2020-04-20 2023-02-14 建新公司 人源化抗补体因子Bb抗体及其用途

Also Published As

Publication number Publication date
PH12018502137A1 (en) 2019-09-23
EP3452510A4 (en) 2020-01-15
MX2018012176A (es) 2019-02-07
MA44878A (fr) 2019-03-13
KR102673420B1 (ko) 2024-06-07
CA3019332A1 (en) 2017-10-12
CN109563158B (zh) 2022-08-09
JP2019513726A (ja) 2019-05-30
IL311675A (en) 2024-05-01
JP7326393B2 (ja) 2023-08-15
KR20240096672A (ko) 2024-06-26
EA201892225A1 (ru) 2019-09-30
SG11201808525UA (en) 2018-10-30
TN2018000341A1 (en) 2020-06-15
US20210221877A1 (en) 2021-07-22
BR112018070357A2 (pt) 2019-01-29
WO2017176651A1 (en) 2017-10-12
DOP2018000219A (es) 2019-03-31
JP2023139289A (ja) 2023-10-03
NZ747018A (en) 2025-05-02
IL262010A (en) 2018-10-31
ECSP18082302A (es) 2019-01-31
IL295288B2 (en) 2024-08-01
CL2018002810A1 (es) 2019-03-15
AU2017246794A1 (en) 2018-10-25
IL295288B1 (en) 2024-04-01
KR20190003951A (ko) 2019-01-10
AU2024224000A1 (en) 2024-12-19
CN116790614A (zh) 2023-09-22
JP2021191789A (ja) 2021-12-16
IL295288A (en) 2022-10-01
EP3452510A1 (en) 2019-03-13
IL262010B (en) 2022-09-01
US20190153079A1 (en) 2019-05-23
MX2023007149A (es) 2023-06-28
US10934347B2 (en) 2021-03-02
US11851482B2 (en) 2023-12-26
CO2018010827A2 (es) 2018-11-22
AU2017246794B2 (en) 2024-07-04
CN109563158A (zh) 2019-04-02
MY194603A (en) 2022-12-06
US20240228599A1 (en) 2024-07-11
CR20180529A (es) 2019-03-21
JP6967528B2 (ja) 2021-11-17

Similar Documents

Publication Publication Date Title
PE20190209A1 (es) Anticuerpos anti-factor bb del complemento y uso de estos
ECSP19086810A (es) Anticuerpos que se unen específicamente a pd-1 y métodos de uso
CY1123972T1 (el) Θεραπεια συνδυασμου για καρκινο
AR131056A2 (es) Composiciones para tratar un trastorno hipofosfatémico
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CY1124004T1 (el) Υποδορια σκευασματα αντισωματων αντι-cd38 και οι χρησεις τους
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
ECSP17063327A (es) Receptores de antígeno quiméricos anti–dll3 y métodos de uso
CO2017005650A2 (es) Anticuerpos anti-interleucina-33
CY1122398T1 (el) Συνδυαστικες θεραπειες με αντισωματα anti-cd38
CY1122721T1 (el) Αντισωματα που δεσμευουν αχl
CY1123065T1 (el) Ανασυνδυασμενα προβιοτικα βακτηριδια
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
CY1123290T1 (el) Ενωσεις και μεθοδοι χρησης
PE20160690A1 (es) Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos
EA202092435A3 (ru) Моноклональные антитела против bcma
MX377716B (es) Moduladores de aplnr y usos de estos.
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
MX2019010574A (es) Anticuerpos anti-c5 y su uso.
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
AR098465A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN
MX2017005553A (es) Terapia de combinacion para cancer.
PE20161390A1 (es) Anticuerpos multiespecificos
PE20150002A1 (es) Anticuerpos anti-fcrn